Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

par Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Publié 2020

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

par Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Publié 2020

Engineering cocrystals of Paliperidone with enhanced solubility and dissolution characteristics

par Radha-Rani Earle, Venkata-Radha Gadela
Publié 2021

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

par Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Publié 2018

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

par Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K
Publié 2020

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia

par Natalia N. Petrova, Valeria S. Serazetdinova
Publié 2020

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review

par Zhang LL, Li JT, Zhao YJ, Su YA, Si TM
Publié 2016

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study

par Shi C, Yao SQ, Xu YF, Shi JG, Xu XF, Zhang CP, Jin H, Yu X
Publié 2016

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparat...

par Li HF, Turkoz I, Zhang F
Publié 2015

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

par Emsley R, Kilian S
Publié 2018

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability

par Gattaz WF, Saracco-Alvarez R, Daltio CS, Van de Bilt MT, Ortegón JJ, Villaseñor-Bayardo SJ, Louzã M, Elkis H, Soares B, Cabrera Jaramillo P, Lawson F, Díaz-Galvis L
Publié 2020

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

par Yang FD, Li J, Tan YL, Liang WY, Zhang R, Wang N, Feng W, Cai S, Zhuo JM, Zhang LL
Publié 2017

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study

par Zhang H, Li H, Liu Y, Wu C, Wu Q, Nuamah I, Shi J, Xie S, Wang G, Gopal S
Publié 2016

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

par Jariyavilas A, Thavichachart N, Kongsakon R, Chantakarn S, Arunpongpaisal S, Chantarasak V, Jaroensook P, Kittiwattanagul K, Nerapusee O
Publié 2017

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia

par Emsley R, Hargarter L, Bergmans P, Uglešić B, Sengül AC, Petralia A, Khannanova A, Cherubin P, Schreiner A
Publié 2017

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

par Such P, Olivares JM, Arias L, Troels Berg M, Madera J
Publié 2021

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study

par Kiss Alexander
Publié 2018

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in...

par Chen CY, Tang TC, Chen TT, Bai YM, Tsai HH, Chen HL, Huang CJ, Chen CK, Chen CC, Hsiao MC, Liu CY, Yeh HS, Chiu NY, Hsiao CC, Chen CS, Su TP
Publié 2018

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

par Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Publié 2017

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

par Brasso C, Bellino S, Bozzatello P, Montemagni C, Rocca P
Publié 2017